Cardiac safety of L-Annamycin: a pooled analysis of five clinical trials
Background Anthracyclines are highly effective chemotherapeutic agents but are limited by cumulative, dose-dependent cardiotoxicity, leading to strict lifetime exposure thresholds. L-Annamycin is a next-generation liposomal anthracycline designed to preserve antitumor efficacy while reducing cardiotoxicity. Methods We...